肝酶作为缓解癌症进展的治疗标
Yogesh Kumar1, Lokesh Gambhir2, Gaurav Sharma1
1School of Applied Sciences, Suresh Gyan Vihar University, Jaipur 302017, Rajasthan, India.
Biochimica et biophysica acta. Reviews on cancer
|September 10, 2025
概括
肝酶是一种促进癌症扩散的酶,是一个有前途的治疗标. 抑制肝酶提供了一种新的策略,可以在癌症治疗中潜在地阻止瘤生长和转移.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 癌症仍然是全球死亡的主要原因,目前的治疗方法面临药物耐药性和毒性等挑战.
- 肝酶是一种降解肝硫酸盐的酶,对瘤入侵,血管新生和转移有显著的作用.
研究的目的:
- 审查肝酶在正常和癌细胞中的发现,结构和功能.
- 探索各种类型的肝酶抑制剂及其在癌症中的治疗潜力.
主要方法:
- 文献综述侧重于肝酶生物学和抑制剂的发展.
- 分析不同类型的抑制剂:基于核酸的多硫酸糖,疫苗,miRNA,单克隆抗体,天然化合物和小分子.
- 检查临床试验进展和专利的肝酶抑制剂.
主要成果:
- 肝酶在癌症进展的多个阶段中发挥着关键作用.
- 不同类型的肝酶抑制剂通过各种机制表现出潜在的抗癌作用.
- 几种肝酶抑制剂已经进入临床试验,表明治疗前景和商业可行性.
结论:
- 抑制肝酶是一种有前途的治疗策略,可以对抗癌症的进展,入侵和转移.
- 继续开发肝酶抑制剂对于推进未来的癌症治疗环境至关重要.
更多相关视频
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
1.8K
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.4K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Metastasis
6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Adaptive Mechanisms in Cancer Cells
7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
